HomeAI · summaries
Storia in 3 fonti
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
ARPA-H launches $160 million effort to develop custom gene editing drugs
An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will get sizable grants.
- ·
endpoints.news
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
ARPA-H taps 7 teams for up to $160M to build bespoke gene editing drugs, betting on Baby KJ's playbook — but some scientists say funding falls short.
- ·
biopharmadive.com
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were…
- ·
Roche ends Huntington's gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout